Location Directory

Clinical trials in New Haven, Connecticut

This page shows live ClinicalTrials.gov search results for New Haven, Connecticut, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1352

Shown on this page

Current sort

Institutions in New Haven

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Yale

Live official records

Open in full search

Conditions: Focal Epilepsy
Interventions: BHV-7000; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 115
States / cities: Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 92 more

Conditions: Hypertension
Interventions: Placebo, lorundrostat Dose 1, lorundrostat Dose 2; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,083 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 87
States / cities: Alexander City, Alabama • Birmingham, Alabama • Foley, Alabama + 74 more

Conditions: Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Interventions: Tarlatamab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 18
States / cities: Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 13 more

Conditions: Depressive Disorder, Violence
Interventions: + Brief ED Intervention (BI), + Text; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 13 Years to 17 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: New Haven, Connecticut • Providence, Rhode Island

Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
Interventions: Bortezomib, Dexamethasone, Elotuzumab, Laboratory Biomarker Analysis, Lenalidomide; Drug · Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 417
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Burbank, California + 261 more

Conditions: Wound Heal, Scar, Scar, Hypertrophic, Keloid, Keloid Scar Following Surgery, Surgical Incision
Interventions: Preoperative silicone ointment, Preoperative placebo ointment; Device · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Tauopathies
Interventions: 11C-M503 PET, Brain MRI, Amyloid PET, Neurological assessments; Drug · Diagnostic Test · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: New Haven, Connecticut • St Louis, Missouri • Philadelphia, Pennsylvania

Conditions: Hepatocellular Carcinoma
Interventions: Pembrolizumab, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 959 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 24
States / cities: Gilbert, Arizona • Tucson, Arizona • Duarte, California + 18 more

Conditions: Breast Cancer
Interventions: Abemaciclib, Standard Adjuvant Endocrine Therapy; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 5,637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 162
States / cities: Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 104 more

Conditions: Gastrointestinal Cancer
Interventions: Raludotatug Deruxtecan (R-DXd); Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: New Haven, Connecticut • Washington D.C., District of Columbia • Miami Beach, Florida + 5 more

Conditions: Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: PF-08046037, sasanlimab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 14
States / cities: Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more

Conditions: Stage I Breast Cancer
Interventions: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane); Other · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 50 Years to 70 Years
Enrollment: 1,670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2041
U.S. locations: 812
States / cities: Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more

Clinical trials in New Haven, Connecticut

Filter and sort this location

Institutions in New Haven

Live official records

Long-term Safety and Tolerability of BHV-7000

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

Intervention to Prevent Peer Violence & Depressive Symptoms Among At-Risk Adolescents

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

Preoperative Silicone Ointment and Wound Healing

Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)